We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+2.14%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.51B
AUM Growth
-$1.16B
Cap. Flow
+$107M
Cap. Flow %
1.43%
Top 10 Hldgs %
57.63%
Holding
98
New
17
Increased
9
Reduced
16
Closed
9

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$165M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$119M
3
ACLX
Arcellx
ACLX
+$80.8M
4
KURA icon
Kura Oncology
KURA
+$64M
5
JANX icon
Janux Therapeutics
JANX
+$63.5M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$230M
2
VRNA
Verona Pharma
VRNA
+$122M
3
EVH icon
Evolent Health
EVH
+$86.8M
4
CGON icon
CG Oncology
CGON
+$52.7M
5
RXRX icon
Recursion Pharmaceuticals
RXRX
+$51.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.36%
2 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SERA icon
51
Sera Prognostics
SERA
$83.4M
$24.7M 0.33%
3,032,808
– –
JBIO
52
Jade Biosciences
JBIO
$1.28B
$24.4M 0.32%
262,631
– –
EYPT icon
53
EyePoint Inc
EYPT
$1.04B
$23.7M 0.32%
+3,181,818
New +$29.6M
LRMR icon
54
Larimar Therapeutics
LRMR
$403M
$23.4M 0.31%
6,045,351
– –
CBLL
55
CeriBell Inc
CBLL
$705M
$21.3M 0.28%
+824,582
New +$22.5M
TVTX icon
56
Travere Therapeutics
TVTX
$5.16B
$20M 0.27%
+1,150,000
New +$20.3M
ELVN icon
57
Enliven Therapeutics
ELVN
$4.17B
$19.1M 0.25%
848,986
-212,247
-20% -$5.5M
TSHA icon
58
Taysha Gene Therapies
TSHA
$1.69B
$18.8M 0.25%
10,872,503
– –
ALEC icon
59
Alector
ALEC
$172M
$18.3M 0.24%
+9,695,228
New +$36.5M
TARA icon
60
Protara Therapeutics
TARA
$229M
$18M 0.24%
3,400,000
+1,500,000
+79% +$4.85M
CCCC icon
61
C4 Therapeutics
CCCC
$396M
$17.6M 0.23%
4,878,000
– –
SLDB icon
62
Solid Biosciences
SLDB
$819M
$17.3M 0.23%
4,330,446
– –
PLRX icon
63
Pliant Therapeutics
PLRX
$65M
$16.9M 0.22%
1,281,000
– –
DRUG
64
Bright Minds Biosciences
DRUG
$742M
$16.6M 0.22%
+460,829
New +$16.2M
ITOS
65
DELISTED
iTeos Therapeutics
ITOS
$16.1M 0.21%
2,092,259
-1,092,452
-34% -$9.39M
BCYC
66
Bicycle Therapeutics
BCYC
$274M
$15.3M 0.2%
1,093,477
-1,159,523
-51% -$24.9M
ELDN icon
67
Eledon Pharmaceuticals
ELDN
$268M
$14.7M 0.2%
+3,566,338
New +$14.1M
INSM icon
68
Insmed
INSM
$21.3B
$13.8M 0.18%
200,000
– –
XNCR icon
69
Xencor
XNCR
$1.47B
$13.2M 0.18%
575,000
– –
IMTX icon
70
Immatics
IMTX
$1.25B
$12.4M 0.17%
1,750,000
– –
ACRS icon
71
Aclaris Therapeutics
ACRS
$792M
$11.6M 0.15%
+4,666,667
New +$11.6M
MNPR icon
72
Monopar Therapeutics
MNPR
$781M
$11.2M 0.15%
+511,207
New +$8.58M
THRD
73
DELISTED
Third Harmonic Bio
THRD
$9.88M 0.13%
960,620
-320,206
-25% -$3.99M
HOWL icon
74
Werewolf Therapeutics
HOWL
$18.7M
$9.09M 0.12%
6,144,881
– –
ARVN icon
75
Arvinas
ARVN
$590M
$8.08M 0.11%
421,348
– –
1 2
3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, RA Capital Management held 98 positions worth $7.51B, down 13% from $8.67B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

RA Capital Management's Q4 2024 filing shows 17 new, 9 increased, 16 reduced and 9 closed positions. Its largest new stake was Septerna Inc: 6,995,858 shares worth $160M. The largest sale was Biogen, an estimated $230M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q4 2024 buy was Septerna Inc: 6,995,858 shares worth $160M.
  • RA Capital Management added most to Arcellx in Q4 2024, an estimated $80.8M increase.
  • RA Capital Management's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $122M.
  • RA Capital Management fully exited Biogen in Q4 2024, selling an estimated $230M.
  • RA Capital Management's ten largest holdings make up 58% of its $7.51B portfolio in Q4 2024.
  • RA Capital Management opened 17 new positions and closed 9 in Q4 2024.
  • RA Capital Management's portfolio value fell 13% quarter-over-quarter to $7.51B.

Based on RA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.